Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new glibenclamide-insensitive neuroselective hyperpolarizing agent

E J Hunnicutt1, J N Davis, J C Chisholm

  • 1Miles Institute for Dementia Research, West Haven, CT 06516.

European Journal of Pharmacology
|August 11, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (EpSSG).

British journal of cancer·2025
Same author

'It's Skin Cancer'… a Rollercoaster of a Journey for Teenagers, Young People and Their Significant Other.

Journal of advanced nursing·2025
Same author

Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.

Virology·2021
Same author

Impact of food security on glycemic control among low-income primarily Hispanic/Latino children in Los Angeles, California: A cross-sectional study.

Journal of hunger & environmental nutrition·2019
Same author

Validity and Reliability of an Expanded Vegetable Questionnaire Among Elementary School Children.

Current developments in nutrition·2019
Same author

Consumption of artificial sweetened beverages associated with adiposity and increasing HbA1c in Hispanic youth.

Clinical obesity·2018
Same journal

Astaxanthin inhibits platelet-mediated thrombosis via suppression of bidirectional αIIbβ3 signaling.

European journal of pharmacology·2026
Same journal

Repurposing of alogliptin to mitigate experimentally-induced ulcerative colitis and its associated pulmonary injury in rats through regulating inflammatory, necroptotic, and ER stress pathways.

European journal of pharmacology·2026
Same journal

Erianin ameliorates liver fibrosis through the PRDX3/NLRX1 axis.

European journal of pharmacology·2026
Same journal

4-Octyl itaconate attenuates renal calculi formation by inhibiting ferroptosis and oxidative stress via the Nrf2-HO-1/SLC7A11 axis.

European journal of pharmacology·2026
Same journal

VER155008 rescues cognitive impairment in P301S tauopathy mice by promoting HSPA8-mediated lipophagy.

European journal of pharmacology·2026
Same journal

Okanin alleviates osteoarthritis by suppressing oxidative stress and pyroptosis via Nrf2/HO-1 activation.

European journal of pharmacology·2026
See all related articles

A novel compound, Bay x9227, shows potent, dose-dependent hyperpolarizing activity selective for CNS neurons. This neuroselective hyperpolarization is a novel pharmacologic target, distinct from K+ATP-channel activators.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • The development of neuroselective agents is crucial for treating neurological disorders.
  • Existing hyperpolarizing agents often lack specificity, affecting various cell types.

Purpose of the Study:

  • To characterize the novel compound Bay x9227 for its hyperpolarizing activity.
  • To investigate the selectivity of Bay x9227 for central nervous system (CNS) neurons.

Main Methods:

  • Utilized single-cell membrane potential measurements with the fluorescent probe bisoxonol.
  • Assessed dose-dependent activity and compared responses with known K+ATP-channel activators.
  • Investigated glibenclamide antagonism to differentiate the mechanism of action.

Related Experiment Videos

Main Results:

  • Bay x9227 exhibited potent hyperpolarizing activity with an EC50 of 3 picomolar.
  • Demonstrated remarkable selectivity for CNS neurons and neurotypic cells over smooth muscle cells.
  • Activity was insensitive to glibenclamide antagonism, distinguishing it from K+ATP-channel activators.

Conclusions:

  • Bay x9227 represents a novel compound with significant neuroselective hyperpolarizing potential.
  • Suggests the existence of a novel pharmacologic site mediating neuroselective hyperpolarization.
  • Offers a potential new therapeutic avenue for CNS-related conditions.